RecruitingPhase 1NCT05684731

Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Principal Investigator
Qinglei Gao, MD. PhD
Tongji Hospital
Intervention
KM1(biological)
Enrollment
30 enrolled
Eligibility
18 years · FEMALE
Timeline
20232026

Study locations (1)

Collaborators

Qilu Hospital of Shandong University · People's Hospital of Quzhou · Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05684731 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials